AccessibilityHelpAbout Us
Cspc Pharmaceutical Group logo

Cspc Pharmaceutical Group(OTC) CHJTF

Market Cap$12.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+233%
5 Year-7%
1 Year-10%
1 Month+16%
$1.11
+0.00%
+0.00Today
Cspc Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeUSD 1.112026-08-19
Cspc Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.74%USD 1.072026-07-24
1 month+15.6%USD 0.962026-06-15
3 month+7.82%USD 1.032026-05-21
Year to date+18.99%USD 0.932025-12-01
1 year-9.54%USD 1.232025-08-19
3 year+51.21%USD 0.732023-08-15
5 year-6.78%USD 1.192021-07-09
Since inception+233.13%USD 0.332003-07-01

Cspc Pharmaceutical Group Financials at a Glance

Market Cap

$12.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥57.57B

Net Income (TTM)

CN¥8.97B

EPS (TTM)

$0.09

P/E Ratio

11.78

Dividend

$0.04

Beta (Volatility)

0.00 (Low)

Price

$1.11

Volume

2,000

Open

$1.11

Previous Close

$1.11

Daily Range

$1.11 - $1.11

52-Week Range

$0.94 - $1.39

Estimated Earnings Date

Nov 19, 2026

CHJTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cspc Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a leading investment holding company focused on the research, development, manufacturing, and global commercialization of pharmaceutical products. With a diverse portfolio, the company operates extensively across various international markets, including Asia, the Americas, and Europe.

Products and Services
  • Finished drugs for various medical conditions, including oncology and cardiovascular health
  • Active pharmaceutical ingredients (APIs) such as antibiotics and vitamin C
  • Functional food items and healthcare services
Growth Outlook
  • Revenue of CNY 18.34 billion in Q2 2026, showing strong market demand
  • Net income margin of 32.77% in Q2 2026, indicating effective cost management
  • Consistent R&D investment, with CNY 2.99 billion in Q2 2026, supporting innovation
Financial Highlights
  • Trailing twelve months (TTM) P/E ratio of 11.66, suggesting attractive valuation
  • Dividend yield of 3.27% TTM, reflecting commitment to shareholder returns
  • Strong cash flow coverage ratio of 4.23, indicating financial stability
CSPC Pharmaceutical Group Limited has established itself as a significant player in the pharmaceutical industry, with a robust product lineup addressing various health conditions. The company's focus on research and development ensures a steady pipeline of innovative products, which is crucial for maintaining competitive advantage in the market. Recent financial performance highlights, including a substantial revenue increase and strong net income margins, underscore the company's operational efficiency and market positioning. With a solid dividend yield and favorable valuation metrics, CSPC presents an intriguing opportunity for potential investors looking to engage with a well-established pharmaceutical entity.
AI Generated • Sep 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

19,700

CEO

Lei Cai, PhD

Website

www.cspc.com.hk

Headquarters

Shijiazhuang, HE 050035, CN

CHJTF Financials

Key Financial Metrics (TTM)

Gross Margin

71.86%

Operating Margin

27.95%

Net Income Margin

23.73%

Return on Equity

20.68%

Return on Capital

11.43%

Return on Assets

13.07%

Earnings Yield

8.49%

Dividend Yield

3.34%

Payout Ratio

33.54%

Stock Overview

Market Cap

$12.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.48B

Volume

2.00K

Avg. Volume

109.375

Financials (TTM)

Gross Profit

CN¥39.52B

Operating Income

CN¥12.89B

EBITDA

CN¥15.51B

Operating Cash Flow

CN¥17.47B

Capital Expenditure

-CN¥3.24B

Free Cash Flow

CN¥14.22B

Cash & ST Invst.

CN¥18.49B

Total Debt

CN¥652.48M

Cspc Pharmaceutical Group Performance Analysis

Cspc Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 4,594,329,9966.3%
20232023-12-31CNY 4,438,953,006-3.4%
20242024-12-31CNY 4,030,844,707-9.2%
20252025-12-31CNY 3,617,746,108-10.2%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-15.8%
Q22025-06-30-5.1%
Q42025-12-31-3.8%
Q22026-06-3046.5%
Cspc Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.084.4%
20232023-12-31CNY 0.07-8.0%
20242024-12-31CNY 0.05-26.6%
20252025-12-31CNY 0.05-7.6%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-59.3%
Q22025-06-30-74.7%
Q42025-12-31331.7%
Q22026-06-30341.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥18.34B

+12.7%

Gross Profit

CN¥13.97B

+19.9%

Gross Margin

76.15%

N/A

Market Cap

$12.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$646.63K

N/A

Employees

19,700

N/A

Net Income

CN¥6.01B

+99.1%

EBITDA

CN¥7.90B

+80.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥18.49B

+71.0%

Total Debt

CN¥652.48M

+67.8%

Accounts Receivable

CN¥8.47B

-28.9%

Inventory

CN¥2.96B

-14.3%

Long Term Debt

CN¥388.98M

+486.6%

Short Term Debt

CN¥263.49M

-18.3%

Return on Assets

13.07%

N/A

Return on Invested Capital

20.73%

N/A

Free Cash Flow

CN¥10.21B

+1215.5%

Operating Cash Flow

CN¥11.01B

+672.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RCDTFRecordati S.p.A.
$58.00+0.00%
ERFSFEurofins Scientific SE
$90.61+0.68%
SGIOYShionogi & Co., Ltd.
$9.27+0.76%
BIOVFSwedish Orphan Biovitrum AB (publ)
$48.13+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.61+4.77%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.95-2.98%
INTCIntel
$124.51-2.26%
AALAmerican Airlines Group
$13.81+3.45%

Questions About CHJTF

What is the current price of Cspc Pharmaceutical Group?

Cspc Pharmaceutical Group is trading at $1.11 per share.

What is the 52-week range for Cspc Pharmaceutical Group?

Over the past 52 weeks, Cspc Pharmaceutical Group has traded between $0.94 and $1.39.

How much debt does Cspc Pharmaceutical Group have?

As of the most recent reporting period, Cspc Pharmaceutical Group reported total debt of CN¥91.74M.

How much cash does Cspc Pharmaceutical Group have on hand?

Cspc Pharmaceutical Group reported CN¥754.52M in cash and cash equivalents in its most recent financial results.

What is Cspc Pharmaceutical Group’s dividend yield?

Cspc Pharmaceutical Group currently has a dividend yield of 3.34%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services